https://www.PR.com/ Latest news releases from PR.com for Vesalio. Wed, 14 Oct 2026 00:08:09 -0400 © 2026 PR.com 60 en-us https://www.PR.com/images/logo_white.jpg https://www.PR.com/ 68 69 PR.com provides press release distribution, and is a unique directory of businesses, products and services. Find full company profiles. https://www.pr.com/press-release/915480 Wed, 10 Jul 2024 07:00:00 -0400 In NeVa NET™, Distal Embolic Filtration and Drop Zone™ technologies work together to enhance clot capture and retention, providing effective recanalization in ischemic stroke thrombectomy. The new NeVa NET 4.0, following the success of the 5.5 mm version, is designed to offer clinicians an advanced tool for improving first-pass rates and reducing distal embolization. [PR.com] https://www.pr.com/press-release/915480 Vesalio https://www.pr.com/press-release/912260 Tue, 21 May 2024 07:00:00 -0400 Vesalio hires J.D. McCulloch as Chief Financial Officer and announces the establishment of the company’s headquarters in Dallas, Texas. [PR.com] https://www.pr.com/press-release/912260 Vesalio https://www.pr.com/press-release/896406 Thu, 21 Sep 2023 12:45:30 -0400 Primary results from the CLEAR Study(1) were presented at the ESMINT annual meeting in Marseille, France (4-6 September 2023), where Vesalio also announced the fifth anniversary of the international commercialization of the NeVa™ device. [PR.com] https://www.pr.com/press-release/896406 Vesalio https://www.pr.com/press-release/880129 Thu, 23 Feb 2023 07:00:00 -0500 Vesalio announces the successful initial use of its NeVa VS device in the United States for the treatment of post-aneurysmal subarachnoid hemorrhage (aSAH) cerebral vasospasm. Vasospasm is the most common complication of aSAH and is the main cause of delayed morbidity and mortality. NeVa VS is the only FDA-approved device for this indication and the only device on the market specifically designed to treat life-threatening [PR.com] https://www.pr.com/press-release/880129 Vesalio https://www.pr.com/press-release/874134 Tue, 29 Nov 2022 07:48:44 -0500 Vesalio hires Bob Bushok as VP of U.S. Sales and announces high first-pass rates and favorable safety profile in a 145-stroke patient data set for the NeVa™ thrombectomy device with findings published in the journal Interventional Neuroradiology. [PR.com] https://www.pr.com/press-release/874134 Vesalio https://www.pr.com/press-release/871404 Thu, 13 Oct 2022 10:21:54 -0400 This regulatory achievement confirms the company’s commitment to the EU’s new, rigorous quality standards for its innovative medical devices. [PR.com] https://www.pr.com/press-release/871404 Vesalio https://www.pr.com/press-release/869534 Thu, 15 Sep 2022 08:00:00 -0400 NeVa VS is a patented retrievable nitinol stent specifically designed to treat cerebral vasospasm after aneurysmal rupture. Delayed cerebral vasospasm is the leading cause of death and disability in patients who suffer an aneurysm rupture. [PR.com] https://www.pr.com/press-release/869534 Vesalio https://www.pr.com/press-release/868560 Thu, 01 Sep 2022 07:15:00 -0400 NeVa NET™ micro-filtration technology coupled with NeVa’s Drop Zone™ technology creates a one-of-a-kind stent retriever designed to capture every type of clot and maximize clot retention for fast and effective recanalization of ischemic tissue. [PR.com] https://www.pr.com/press-release/868560 Vesalio https://www.pr.com/press-release/861618 Wed, 18 May 2022 10:46:00 -0400 Vesalio, an emerging leader in improving outcomes in patients with vascular occlusion, is proud to announce it has oversubscribed its Class A financing round. Solas BioVentures led the investment with participation by new and existing investors, including the recent addition of Orlando Health Ventures. With an expanding customer base established in Europe, Vesalio will use this funding to enter the U.S. market by [PR.com] https://www.pr.com/press-release/861618 Vesalio https://www.pr.com/press-release/861148 Wed, 11 May 2022 08:42:24 -0400 Vesalio announces the completion of enrollment in its FDA IDE clinical study for acute ischemic stroke. [PR.com] https://www.pr.com/press-release/861148 Vesalio https://www.pr.com/press-release/854415 Thu, 03 Feb 2022 14:54:52 -0500 As a board observer and senior advisor to the company, Earl Slee brings extensive medical device innovation and business development expertise. [PR.com] https://www.pr.com/press-release/854415 Vesalio https://www.pr.com/press-release/853327 Wed, 19 Jan 2022 13:16:53 -0500 As an independent board chairman, Mike Kujak brings extensive medical start-up expertise. [PR.com] https://www.pr.com/press-release/853327 Vesalio https://www.pr.com/press-release/851876 Thu, 23 Dec 2021 12:42:41 -0500 Vesalio Initiates Clinical Study Evaluating Innovative Thrombectomy Technique for Patients with STEMI. [PR.com] https://www.pr.com/press-release/851876 Vesalio https://www.pr.com/press-release/837614 Wed, 02 Jun 2021 09:00:43 -0400 Vesalio Secures Class A Funding [PR.com] https://www.pr.com/press-release/837614 Vesalio https://www.pr.com/press-release/836333 Tue, 11 May 2021 13:14:23 -0400 Vesalio announces another key milestone to support entry into the US neurovascular thrombectomy market. Enrollment has commenced in the Vesalio CLEAR(1) acute ischemic stroke FDA IDE clinical trial utilizing the NeVa(TM) thrombectomy technology platform. With twenty participating stroke treatment centers, enrollment is expected to be completed in early 2022. Ischemic stroke is caused when a blood clot blocks an artery in [PR.com] https://www.pr.com/press-release/836333 Vesalio https://www.pr.com/press-release/835567 Wed, 28 Apr 2021 14:03:52 -0400 Vesalio announces it has accomplished a key FDA IDE study milestone to support entry into the US neurovascular market. Enrollment in the VITAL(1) clinical trial, assessing the company’s NeVa VS™ technology in the treatment of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH), has been completed. Cerebral vasospasm is an intense and prolonged narrowing of the arteries that [PR.com] https://www.pr.com/press-release/835567 Vesalio https://www.pr.com/press-release/829944 Thu, 28 Jan 2021 13:55:45 -0500 Vesalio reports it has obtained an FDA 510k clearance and its 4th CE approval. The FDA 510k indication is for the removal of thrombi in peripheral blood vessels. The new CE approval expands the NeVa™ neuro-thrombectomy portfolio. Vesalio’s Drop Zone(TM) technology, designed to remove the full spectrum of clots from vascular anatomy, has been acclaimed for consistently achieving high first-pass rates, a key [PR.com] https://www.pr.com/press-release/829944 Vesalio https://www.pr.com/press-release/826854 Mon, 07 Dec 2020 14:09:21 -0500 Vesalio reports it has surpassed 2,500 clinical cases with the NeVa™ neuro-thrombectomy platform. Physicians have evaluated the Neva Drop Zone™ technology with enthusiasm as it has shown a unique capability of removing the full spectrum of clot types in large vessel occlusion ischemic stroke. “We are delighted to reach this milestone in just over two years of our European launch at ESMINT 2018. Vesalio [PR.com] https://www.pr.com/press-release/826854 Vesalio https://www.pr.com/press-release/821437 Wed, 16 Sep 2020 15:10:19 -0400 Vesalio Expands Sales Network, Initiates Virtual Physician Training and Announces High First Pass Effect Rate Publication [PR.com] https://www.pr.com/press-release/821437 Vesalio https://www.pr.com/press-release/785673 Wed, 22 May 2019 10:23:24 -0400 Vesalio announces it has obtained its second CE mark approval spanning multiple new NeVa™ neurothrombectomy product designs and technology. The new generation NeVa devices expand on the Drop Zone™ and Smart Marker™ technologies while also introducing first-to-market features such as a distal filter. A controlled launch of the newly approved products will begin in June in Europe with expected full [PR.com] https://www.pr.com/press-release/785673 Vesalio https://www.pr.com/press-release/785002 Tue, 14 May 2019 14:40:09 -0400 Vesalio announces it has recently raised $5 million in funding. The capital will support the continued global expansion of the NeVa™ Neurothrombectomy System, finance key clinical studies and launch new product introductions. “We are very pleased to secure the additional capital funding, which affirms our track record of achievement and the promising clinical results physicians are seeing with NeVa. We are in [PR.com] https://www.pr.com/press-release/785002 Vesalio https://www.pr.com/press-release/781553 Tue, 02 Apr 2019 13:44:18 -0400 Vesalio announces it has executed multiple exclusive distribution agreements in Europe, Latin America, Asia and the Middle East and now has market coverage in 39 countries for the NeVa™ Neuro-thrombectomy System. Along with the increased market and registration activities, Vesalio is expanding its training programs to include Vesalio Clot Interaction Labs™ and AIS Simulation Workshops with Vesalio’s [PR.com] https://www.pr.com/press-release/781553 Vesalio https://www.pr.com/press-release/764589 Wed, 12 Sep 2018 18:14:52 -0400 Vesalio Initiates Full Commercial Launch of NeVa at ESMINT Congress [PR.com] https://www.pr.com/press-release/764589 Vesalio https://www.pr.com/press-release/756983 Mon, 18 Jun 2018 19:07:12 -0400 Vesalio announces it has executed multiple exclusive distribution agreements in Europe and now has market coverage in 25 countries for the NeVa Neurothrombectomy System. All channel partners have been trained on the unique features of the NeVa platform and technique that is optimized for capturing all clot types in the first pass. With a successful controlled launch in the EU, Vesalio is now rapidly expanding the [PR.com] https://www.pr.com/press-release/756983 Vesalio https://www.pr.com/press-release/748571 Thu, 22 Mar 2018 12:06:41 -0400 Vesalio announces it has completed European enrollment of the first twenty-five human cases in a post-market registry of the proprietary NeVa™ neurothrombectomy platform for the treatment of stroke. With procedures performed at six centers in four countries to date, early results demonstrate superior first pass clot removal and TICI 2b – 3 recanalization. These results are consistent with improved efficacy [PR.com] https://www.pr.com/press-release/748571 Vesalio https://www.pr.com/press-release/734724 Tue, 31 Oct 2017 15:20:29 -0400 Vesalio announces the CE Mark certification of its first product line, the proprietary NeVa™ neurothrombectomy platform for the treatment of strokes. Developed by a team of physicians that treat stroke, the NeVa mechanical thrombectomy technology was designed to improve “first pass” success, by effectively capturing and removing a clot that creates a sudden blockage in the blood flow to the brain. The [PR.com] https://www.pr.com/press-release/734724 Vesalio